Mereo BioPharma Group plc
MREO
$0.32
$0.013.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.73% | -34.97% | -2.55% | -30.17% | 23.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.29% | -48.18% | 7.89% | -17.61% | 16.92% |
| Operating Income | 21.29% | 48.18% | -7.89% | 21.62% | -16.92% |
| Income Before Tax | 47.86% | -4.33% | 53.18% | -19.27% | -43.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.86% | -4.33% | 53.18% | -19.27% | -43.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.86% | -4.33% | 53.18% | -19.27% | -43.97% |
| EBIT | 21.29% | 48.18% | -7.89% | 21.62% | -16.92% |
| EBITDA | 21.82% | 50.81% | -9.13% | 22.10% | -17.24% |
| EPS Basic | 49.03% | -0.88% | 54.93% | -6.16% | -28.64% |
| Normalized Basic EPS | 48.93% | -1.06% | 55.01% | -6.13% | -28.57% |
| EPS Diluted | 49.03% | -0.88% | 54.93% | -6.16% | -28.64% |
| Normalized Diluted EPS | 48.93% | -1.06% | 55.01% | -6.13% | -28.57% |
| Average Basic Shares Outstanding | 2.23% | 3.27% | 3.87% | 12.32% | 12.00% |
| Average Diluted Shares Outstanding | 2.23% | 3.27% | 3.87% | 12.32% | 12.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |